$Loxo Oncology, Inc. (LOXO)$ reported much better MTC RET altered data at ATA. They increased the ASCO reported response rate to 59% from 45%. This was the result of 7 additional responses of which 5 were from previously evaluated patients. This is an important caveat as the $Loxo Oncology, Inc. (LOXO)$  trial is different than $Blueprint Medicines Corporation(BPMC)$ . In the LOXO trial patients who do not respond at lower doses can get higher doses, which certainly explains why 5 of the previously evaluated patients are now responding. The BPMC trial does not allow that increased dosing for non-responders, so this is not an apple-to-apples comparison.